Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT04171219
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Advanced Malignant Solid Neoplasm
- Recurrent Malignant Solid Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pembrolizumab — BIOLOGICALGiven IV
- Talabostat Mesylate — DRUGGiven PO
Study Details
This phase II trial studies the side effects of talabostat and pembrolizumab and to see how well they work for the treatment of solid cancers that have spread to other places in the body (advanced). Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talabostat and pembrolizumab may help control the disease.
Key Dates
- Start date
- Mar 19, 2020
- Status verified
- May 2025
- Primary completion
- Mar 11, 2025
- Completion
- Mar 11, 2025
Study Design
- Enrollment
- 31 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (talabostat, pembrolizumab)Patients receive talabostat PO BID on days 1-14 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Disease Control Rate Per RECIST v1.1 [ Time Frame: At baseline and at the end of Cycle 3 (approximately 9 weeks after the first study treatment dose), and then approximately every 9 weeks thereafter until development of progressive disease, up to 3 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | - |
Related coverage on Hipa.ai
- Pembrolizumab + Talabostat Phase 2 Trial for Advanced Solid Cancers TerminatedPembrolizumab · May 16, 2025 · ClinicalTrials.gov
Find similar trials in Houston, TX
Related Studies
- Collection and Storage of Tissue and Blood Samples From Patients With CancerRecruiting · National Cancer Institute LAO · Birmingham, Alabama
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialPHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPHASE1/PHASE2 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaPHASE1/PHASE2 · Recruiting · Children's Oncology Group · Birmingham, Alabama